This site is intended for U.S. audiences only.

About glioma

Glioma is the most common type of malignant brain tumor.

Around 2,400 people are diagnosed with IDH-mutant gliomas in the United States every year.

What does it mean to have an IDH mutation?

A diagnosis of astrocytoma or oligodendroglioma requires a mutation in the IDH gene to be present. Prognosis varies between different types of glioma depending on the mutations it may have. The prognosis is usually better for astrocytoma and oligodendroglioma than for glioma without an IDH mutation.

Astrocytomas and oligodendrogliomas tend to grow more slowly than glioblastomas and should be checked with an MRI scan every 2 to 6 months. In addition to a radiologist, your neuro-oncologist, neurosurgeon, oncologist, or neurologist may also evaluate the images to check for tumor growth so your healthcare team can make informed decisions with you about your treatment.

Why is it important to find out if my glioma has an IDH mutation?

The presence of an IDH mutation can affect treatment decisions.

A tumor tissue sample will be sent to a pathologist to analyze under a microscope and to identify mutations such as IDH. The most common IDH mutation can be found with IHC, and less common mutations must be identified with NGS.

If you are under 55, you should ask if your tumor was tested for all possible IDH mutations.

If it has a been long time since your first test, ask if your tumor can be retested.

Download the Glioma Overview Brochure to learn more about mutations in glioma

Download

VORANIGO is the first treatment to target mutant IDH1/2 enzymes in gliomas.

Learn more

ServierONE Patient Support Services

ServierONE offers patients helpful resources and tools for navigating treatment, costs, and education throughout their journeys, including a VORANIGO copay program.

For more information:

Visit

ServierONE.com

USPatientServices@servier.com

Call

1-800-813-5905

Monday-Friday, 8 AM to 8 PM ET

What is VORANIGO?

VORANIGO (40 mg tablets) is a prescription medicine used to treat adults and children 12 years of age and older with certain types of brain tumors called astrocytoma or oligodendroglioma with an isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation, following surgery. Your healthcare provider will perform a test to make sure that VORANIGO is right for you. It is not known if VORANIGO is safe and effective in children under 12 years of age.

What are the possible side effects of VORANIGO?

VORANIGO may cause serious side effects, including:

Liver problems. Changes in liver function blood tests may happen during treatment with VORANIGO and can be serious. Your healthcare provider will do blood tests to check your liver function before and during treatment with VORANIGO. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems:

yellowing of your skin or the white part of your eyes (jaundice)

dark tea-colored urine

loss of appetite

pain on the upper right side of your stomach area

feeling very tired or weak

The most common side effects of VORANIGO include:

increased liver enzyme levels in the blood

lack of energy, tiredness

headache

COVID-19

muscle aches or stiffness

diarrhea

nausea

seizure

Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with VORANIGO if you have certain side effects.

VORANIGO may affect fertility in females and males, which may affect the ability to have children. Talk to your healthcare provider if this is a concern for you.

These are not all of the possible side effects of VORANIGO.

Before taking VORANIGO, tell your healthcare provider about all of your medical conditions, including if you:

have liver problems

have kidney problems or are on dialysis

smoke tobacco

are pregnant or plan to become pregnant. VORANIGO can harm your unborn baby

Females who are able to become pregnant:

Your healthcare provider will do a pregnancy test before you start treatment with VORANIGO

You should use effective nonhormonal birth control during treatment with VORANIGO and for 3 months after the last dose. VORANIGO may affect how hormonal contraceptives (birth control) work and cause them to not work well. Talk to your healthcare provider about birth control methods that may be right for you during treatment with VORANIGO

Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with VORANIGO

Males with female partners who are able to become pregnant:

You should use effective birth control during treatment with VORANIGO and for 3 months after the last dose

Tell your healthcare provider right away if your partner becomes pregnant or thinks she may be pregnant during your treatment with VORANIGO

Tell your healthcare provider if you are breastfeeding or plan to breastfeed. It is not known if VORANIGO passes into breast milk. Do not breastfeed during treatment with VORANIGO and for 2 months after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VORANIGO may affect the way other medicines work, and other medicines may affect how VORANIGO works.

Please see Full Prescribing Information.